| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
Access to innovation through clinical trials and the national early access program for patients with lung cancer in France: focus on atezolizumab and durvalumab
|
Jacquet, Emmanuelle
|
|
|
92 |
3 |
p. 223-228
|
artikel
|
| 2 |
Cabozantinib-induced serum creatine kinase elevation and rhabdomyolysis: a retrospective case series
|
Yamanaka, Taro
|
|
|
92 |
3 |
p. 235-240
|
artikel
|
| 3 |
External validation of a tumor growth inhibition-overall survival model in non-small-cell lung cancer based on atezolizumab studies using alectinib data
|
Kassir, Nastya
|
|
|
92 |
3 |
p. 205-210
|
artikel
|
| 4 |
Infections occurring following IL6 blockade for the management of cytokine release syndrome in onco-hematology patients
|
Valery, M.
|
|
|
92 |
3 |
p. 229-233
|
artikel
|
| 5 |
Phase I study to assess the effect of adavosertib (AZD1775) on the pharmacokinetics of substrates of CYP1A2, CYP2C19, and CYP3A in patients with advanced solid tumors
|
Någård, Mats
|
|
|
92 |
3 |
p. 193-203
|
artikel
|
| 6 |
Population pharmacokinetics and toxicity correlation analysis of free and liposome-encapsulated doxorubicin in Chinese patients with advanced breast cancer
|
Xu, Gaoqi
|
|
|
92 |
3 |
p. 181-192
|
artikel
|
| 7 |
Therapeutic drug monitoring of immune checkpoint inhibitors: based on their pharmacokinetic properties and biomarkers
|
Liu, Dongxue
|
|
|
92 |
3 |
p. 165-179
|
artikel
|
| 8 |
Veratricplatin inhibits the progression of hypopharyngeal squamous cell carcinoma FaDu cells in vitro and in vivo
|
Wang, Dongbo
|
|
|
92 |
3 |
p. 211-221
|
artikel
|
Tijdschrift beschrijving